Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study to Assess the Safety, Efficacy, and Immunogenicity of Authentic SARS-CoV-2 or Alpha Variant Spike Containing VLP Vaccines and Their Combination for the Prevention of COVID-19 in Healthy Adult Volunteers (SAVE STUDY)

NCT04962893 is registered in ClinicalTrials.gov with Ihsan GURSEL, PhD, Prof. as lead sponsor.

NCT NCT04962893
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04962893 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study to Assess the Safety, Efficacy, and Immunogenicity of Authentic SARS-CoV-2 or Alpha Variant Spike Containing VLP Vaccines and Their Combination for the Prevention of COVID-19 in Healthy Adult Volunteers (SAVE STUDY)
Lead sponsor
Ihsan GURSEL, PhD, Prof.
Phase
Phase 2
Overall status
Completed
Start date
June 26, 2021
Completion date
January 16, 2022
Enrollment
349 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

covid19